Evaluation of Pharmacokinetic Interactions between Levonorgestrel Vaginal Delivery System and Tampons and Lubricants in Healthy Female Subjects

The primary objective of this study is to evaluate the **drug-drug interactions** between the Levonorgestrel Vaginal Delivery System (LVDS) and the use of tampons and lubricants in healthy female participants. Understanding these interactions is clinically relevant as it may impact the efficacy and safety of the LVDS, which is used for contraception. The study does not involve participants with any specific medical condition, focusing instead on healthy individuals to assess the potential interactions in a controlled environment.

The clinical trial involves a study population consisting exclusively of **female** participants, with an age range categorized as 3, which typically corresponds to a specific age group as defined in clinical research. The trial population is identified as a vulnerable group, indicating that special considerations are taken into account for their protection and ethical treatment. The sponsor has not provided information regarding the total number of participants involved in the study. Participants were selected based on criteria that ensure the inclusion of individuals without any specific **medical condition**. Lifestyle factors such as diet, physical activity, or habits have not been specified in the available data. The trial does not include male participants, and no further details on the selection process or additional inclusion or exclusion criteria have been disclosed by the sponsor.

The clinical trial is designed to evaluate **drug-drug interactions** between the Levonorgestrel Vaginal Delivery System (LVDS) and tampons and lubricants in healthy female participants. This study is a Phase 3 trial, which is a critical stage in the clinical research process, focusing on the efficacy and safety of the intervention. The trial is structured as a randomized, double-blind, controlled study to ensure the reliability and validity of the results. The estimated recruitment start date is April 25, 2025, with an anticipated end date of September 13, 2025, indicating a total trial duration of approximately five months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into different study arms. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health status and collect data on the interaction between LVDS and the other products. The end-of-study visit will conclude the trial, where final assessments will be conducted to gather comprehensive data for analysis.

The expected length of participant involvement is aligned with the overall trial duration, subject to individual adherence to the study protocol. Conditions that may lead to early termination from the study include non-compliance with study procedures, adverse events that compromise participant safety, or withdrawal of consent. The trial is conducted with no underlying medical condition as a prerequisite, ensuring the focus remains on the interaction effects of the products under investigation.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on April 25, 2025, with an estimated end date of September 13, 2025. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters at predetermined timepoints throughout the study duration. The trial's design and execution will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy assessments.